Title : Comparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunction.

Pub. Date : 2015 Jun

PMID : 26029452






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 CONCLUSIONS: Patients with CP-A or CP-B advanced HCC should be offered sorafenib at 400 mg twice daily with optimal management of AEs in order to improve survival. Sorafenib carboxypeptidase A1 Homo sapiens